Assessment and diagnostic relevance of novel serum biomarkers for early decision of ST-elevation myocardial infarction

Abstract

Blood transcriptome reflects the status of diseases, and characteristic molecular signature provides a novel window on gene expression preceding acute coronary events. We aim to determine blood transcriptome-based molecular signature of acute coronary syndrome (ACS), and to identify novel serum biomarkers for early stage ST-segment-elevation myocardial infarction (STEMI). We obtained peripheral blood from the patients with ACS who visited emergency department within 4 hours after the onset of chest pain: STEMI (n = 10), Non-ST-segment-elevation MI (NSTEMI, n = 10) and unstable angina (UA, n = 11). Blood transcriptome scans revealed that a characteristic gene expression change exists in STEMI, resulting in 531 outlier genes as STEMI molecular signature (Welch's t test, P < 0.05). Another analysis with a set of blood samples of patients with STEMI (n = 7) before and 7 days after the primary percutaneous coronary intervention (n = 7) and normal control (n = 10) evidenced that STEMI molecular signature directly reflects the onset of STEMI pathogenesis. From the two sets of transcriptome-based STEMI signatures, we identified 10 genes encoding transmembrane or secretory proteins that are highly expressed in STEMI. We validated blood protein expression levels of these 10 putative biomarkers in 40 STEMI and 32 healthy subjects by ELISA. Data suggested that PGLYRP1, IRAK3 and VNN3 are more specific and sensitive diagnostic biomarkers for STEMI than traditional CK-MB or troponin.Blood transcriptome scans of ACS evidenced early stage molecular markers for STEMI. Here, we report novel biomarkers to diagnose STEMI at emergency department in hospitals by a simple ELISA method.

Association Between Peptidoglycan Recognition Protein-1 and Incident Atherosclerotic Cardiovascular Disease Events

“…We previously showed that circulating PGLYRP-1 levels were associated with prevalent subclinical atherosclerosis in humans as evidenced by coronary artery calcium and abdominal aortic wall thickness (3). More recently, a blood transcriptome study identified PGLYRP-1 in patients with acute coronary syndromes (4). These associations with prevalent subclinical and acute atherosclerotic disease suggest a potential role for PGLYRP-1 as an atherosclerosis biomarker.…”

Screening genes associated with elevated neutrophil‑to‑lymphocyte ratio in chronic heart failure

“…Moreover, the vanin family gene VNN3 is a secreted and membrane-bound ectoenzyme which converts pantetheine into pantothenic acid and cysteamine. A previous study screening a blood transcriptome-based molecular signature demonstrated that VNN3 may serve as a more specific and sensitive diagnostic biomarker for ST-segment-elevation myocardial infarction than traditional creatine kinase-MB or troponin ( 29 ). Additionally, the expression of VNN3 was also found to be upregulated in mesangial proliferative nephritis and skin psoriasis lesions, suggesting its proinflammatory activity in diseases ( 30 , 31 ).…”

Screening hub genes in coronary artery disease based on integrated analysis

“…Interleukin 1 receptor type 2 (IL1R2) is an anti-inflammatory gene [15]. It is pointed out that the expression of IL1R2 is remarkably up-regulated in ST-segment elevation myocardial infarction [16]. It is also upregulated in peripheral blood mononuclear cells and whole blood in patients with advanced heart failure [17].…”